Abstract
Several myelin-associated proteins in the central nervous system (CNS) have been identified as inhibitors of axonal regeneration following the injury of the adult vertebrate CNS. Among these inhibitors, myelin-associated glycoprotein (MAG), Nogo, and oligodendrocyte- myelin glycoprotein (OMgp) are well characterized. Recently, the repulsive guidance molecule (RGM) was included as a potent myelin-derived neurite outgrowth inhibitor in vitro and in vivo. The discovery of the receptors and downstream signals of these inhibitors enabled further understanding of the mechanism underlying the failure of axonal regeneration. The activation of RhoA and its effector Rho kinases (ROCK) after the ligation of these inhibitors to the corresponding receptors has been shown to be a key element for axonal growth inhibition. Blockade of the Rho-ROCK pathway reverses the inhibitory effects of these inhibitors in vitro and promotes axonal regeneration in vivo. Therefore, the Rho-ROCK inhibitors have a therapeutic potential against injuries to the human CNS, such as spinal cord injuries.
Keywords: Myelin, p75, Rho, repulsive guidance molecule, regeneration, central nervous system
Current Pharmaceutical Design
Title: Rho-ROCK Inhibitors as Emerging Strategies to Promote Nerve Regeneration
Volume: 13 Issue: 24
Author(s): Takekazu Kubo, Katsuhiko Hata, Atsushi Yamaguchi and Toshihide Yamashita
Affiliation:
Keywords: Myelin, p75, Rho, repulsive guidance molecule, regeneration, central nervous system
Abstract: Several myelin-associated proteins in the central nervous system (CNS) have been identified as inhibitors of axonal regeneration following the injury of the adult vertebrate CNS. Among these inhibitors, myelin-associated glycoprotein (MAG), Nogo, and oligodendrocyte- myelin glycoprotein (OMgp) are well characterized. Recently, the repulsive guidance molecule (RGM) was included as a potent myelin-derived neurite outgrowth inhibitor in vitro and in vivo. The discovery of the receptors and downstream signals of these inhibitors enabled further understanding of the mechanism underlying the failure of axonal regeneration. The activation of RhoA and its effector Rho kinases (ROCK) after the ligation of these inhibitors to the corresponding receptors has been shown to be a key element for axonal growth inhibition. Blockade of the Rho-ROCK pathway reverses the inhibitory effects of these inhibitors in vitro and promotes axonal regeneration in vivo. Therefore, the Rho-ROCK inhibitors have a therapeutic potential against injuries to the human CNS, such as spinal cord injuries.
Export Options
About this article
Cite this article as:
Takekazu Kubo , Katsuhiko Hata , Atsushi Yamaguchi and Toshihide Yamashita , Rho-ROCK Inhibitors as Emerging Strategies to Promote Nerve Regeneration, Current Pharmaceutical Design 2007; 13 (24) . https://dx.doi.org/10.2174/138161207781368657
DOI https://dx.doi.org/10.2174/138161207781368657 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: New Avenues of Research on Multiple Sclerosis from the Perspective of Chronic Cerebrospinal Venous Insufficiency Paradigm (Guest Editor: Marian Simka)]
Reviews on Recent Clinical Trials Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury
Current Medicinal Chemistry Cardiovascular Consequences of Weightlessness Promote Advances in Clinical and Trauma Care
Current Pharmaceutical Biotechnology Heart Failure Modulates the Muscle Reflex
Current Cardiology Reviews Recent Patents on Mesenchymal Stem Cell Mediated Therapy in Inflammatory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery The Bioanalytical Molecular Pharmacology of the N-methyl-<sub>D</sub>-Aspartate (NMDA) Receptor Nexus and the Oxygen-Responsive Transcription Factor HIF-1α : Putative Mechanisms and Regulatory Pathways Unravel the Intimate Hypoxia Connection
Current Molecular Pharmacology Commentary: Low-Grade Non-Resolving Neuroinflammation: Age Does Matter
CNS & Neurological Disorders - Drug Targets Animal Peptides Targeting Voltage-Activated Sodium Channels
Current Pharmaceutical Design Vital Elements of the Wnt-Frizzled Signaling Pathway in the Nervous System
Current Neurovascular Research Role of Immune Cells in the Course of Central Nervous System Injury: Modulation with Natural Products
Current Pharmaceutical Design Adult Neural Stem Cells: Response to Stroke Injury and Potential for Therapeutic Applications
Current Stem Cell Research & Therapy The Timing of Drug Administration for Thromboprophylaxis Following Orthopaedic Surgery: Evidence and Controversies Related to Treatment Initiation and Duration
Current Vascular Pharmacology New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Role of Secretory Phospholipase A2 in CNS Inflammation: Implications in Traumatic Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Nerve Growth Factor: Structure, Function and Therapeutic Implications for Alzheimers Disease
Current Drug Targets - CNS & Neurological Disorders Sexual Dimorphism in Autoimmune Disease
Current Molecular Medicine Restless Legs Syndrome/Willis-Ekbom Disease and Periodic Limb Movements: A Comprehensive Review of Epidemiology, Pathophysiology, Diagnosis and Treatment Considerations
Current Rheumatology Reviews Botulinum Toxin as a Neuro-Relearning Drug Tool in Motor Paralytic Disorders
Current Drug Therapy Cell Death: Tipping the Balance of Autoimmunity and Tissue Repair
Current Pharmaceutical Design Granulocyte Colony-Stimulating Factor Attenuates Blood-Brain Barrier Damage and Improves Cognitive Function in Spontaneously Hypertensive Rats
CNS & Neurological Disorders - Drug Targets